JW Group Joins Hands with U.S. Venture Capital to Promote Open Innovation
The Business Korea website reported that the JW Group has signed a business agreement with ARCH Venture Partners, a U.S. venture capital to promote open innovation with global biotech companies. This is the first time that a Korean pharmaceutical company has joined hands with a biotech and healthcare venture capital firm in the United States to promote open innovation in basic research. JW Group is planning to expand its open innovation partners to global biotech giants by utilizing the ARCH Technical Service, which provides technical information of promising biotech companies to strategic investors interested in business cooperation with venture companies.
Click here to read the full article.